Announcements

25 September 2025
Antibodies | Top 10 Cited Papers in 2024


1. “Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria”
by Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
Antibodies 2024, 13(1), 21; https://doi.org/10.3390/antib13010021
Available online: https://www.mdpi.com/2073-4468/13/1/21

2. “Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development”
by Tsvetelina Velikova, Metodija Sekulovski and Monika Peshevska-Sekulovska
Antibodies 2024, 13(1), 16; https://doi.org/10.3390/antib13010016
Available online: https://www.mdpi.com/2073-4468/13/1/16

3. “Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database”
by Connor Frey and Mahyar Etminan
Antibodies 2024, 13(3), 59; https://doi.org/10.3390/antib13030059
Available online: https://www.mdpi.com/2073-4468/13/3/59

4. “Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature”
by Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier
Antibodies 2024, 13(1), 1; https://doi.org/10.3390/antib13010001
Available online: https://www.mdpi.com/2073-4468/13/1/1

5. “Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management”
by Panagiotis Gklinos and Ruth Dobson
Antibodies 2024, 13(2), 43; https://doi.org/10.3390/antib13020043
Available online: https://www.mdpi.com/2073-4468/13/2/43

6. “A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments”
by Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri
Antibodies 2024, 13(2), 32; https://doi.org/10.3390/antib13020032
Available online: https://www.mdpi.com/2073-4468/13/2/32

7. “Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules”
by Francesco Ferrara, Chiara Verduci, Emanuela Laconi, Andrea Mangione, Chiara Dondi, Marta Del Vecchio, Veronica Carlevatti, Andrea Zovi, Maurizio Capuozzo and Roberto Langella
Antibodies 2024, 13(3), 76; https://doi.org/10.3390/antib13030076
Available online: https://www.mdpi.com/2073-4468/13/3/76

8. “Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature”
by Panagiotis Gklinos, Fotios Athanasopoulos, Vagia Giatrakou, Nikolaos-Achilleas Arkoudis, Dorothea Pournara, Eirini Giagkou, Argyro Tountopoulou, Sofia Vassilopoulou and Dimos-Dimitrios Mitsikostas
Antibodies 2024, 13(4), 79; https://doi.org/10.3390/antib13040079
Available online: https://www.mdpi.com/2073-4468/13/4/79

9. “A Comparison of Natural and Therapeutic Anti-IgE Antibodies”
by Monique Vogel and Paul Engeroff
Antibodies 2024, 13(3), 58; https://doi.org/10.3390/antib13030058
Available online: https://www.mdpi.com/2073-4468/13/3/58

10. “TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth”
by Amrendra K. Ajay, Martin Gasser, Li-Li Hsiao, Thomas Böldicke and Ana Maria Waaga-Gasser
Antibodies 2024, 13(1), 11; https://doi.org/10.3390/antib13010011
Available online: https://www.mdpi.com/2073-4468/13/1/11

3 September 2025
Join Us at the MDPI at the University of Toronto Career Fair, 23 September 2025, Toronto, ON, Canada


Date: 23 September 2025
Time: 11:00 a.m.–4:30 p.m
Location: The Chelsea Hotel, 33 Gerrard Street West, Toronto

MDPI is thrilled to announce our participation in the University of Toronto’s largest career fair, taking place at the St. George Downtown Campus. This exciting event brings together thousands of students, graduates, and professionals looking to connect with top employers and explore career opportunities.

We invite all attendees to visit the MDPI booth to discover how you can be part of one of the world’s leading open access academic publishers. Whether you are passionate about scientific research, editorial work, marketing, or supporting global innovation in publishing, we want to meet YOU!

What to expect at our booth:

  • Learn more about MDPI’s mission and global impact;
  • Explore exciting career opportunities in publishing, editorial, communications, and more;
  • Network with our team and ask questions about working at MDPI.

Whether you’re just starting your career or looking to take the next step, don’t miss this opportunity to connect with MDPI. Bring your resume, your curiosity, and your questions—we look forward to seeing you there!

For additional information on the Career Fair and Open MDPI positions, please visit the following links:

1 September 2025
MDPI INSIGHTS: The CEO’s Letter #26 – CUJS, Head of Ethics, Open Peer Review, AIS 2025, Reviewer Recognition

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Society of China University Journals (CUJS) visit to MDPI Basel

In August, we had the pleasure of welcoming a delegation from the Society of China University Journals (CUJS) to our Basel headquarters. The visit was part of CUJS’s broader European tour, which included meetings with several major publishing organizations.

Purpose of the visit

The delegation’s stop in Basel involved an introductory meeting and knowledge-sharing with a view to identifying potential collaboration opportunities with MDPI. The CUJS team shared an overview of the Chinese scientific publishing landscape, including recent policy developments, and gave us insights into the journals and services they operate across China’s academic institutions.

MDPI presentations

We used the opportunity to introduce CUJS to MDPI’s mission, structure, and recent achievements. I presented on the latest developments at MDPI and our role in supporting global open access, addressing many follow-up questions from the delegation. Warm thanks are due to the following colleagues for their contributions to the session:

  • Liliane Auwerter (Conference Organizer, Scientific Officer and Sustainability Specialist) shared an overview of our editorial process, including the quality indicators we use to track peer-review performance.
  • Renato Merki (Publication Ethics Assistant) presented on behalf of our Research Integrity and Ethics team, emphasizing our commitment to responsible publishing.
  • Silvano Bonfatti (Product Manager) introduced the JAMS platform, highlighting how it supports efficient journal management for editors and publishers alike.
  • Aimar Xiong (Publisher, Section Managing Editor) and Giuliano Braccini (Office Manager) facilitated the meeting, offering clarity in response to specific questions, building the relationship during and beyond the meeting itself.

“Building relationships with organizations such as CUJS allows us to increase our visibility and reputation”

Why is this important?

China is one of the world’s largest producers of scientific research, with its universities and research institutes playing a key role in global scholarly publishing. Building strong relationships with influential organizations such as CUJS allows us to increase our visibility and reputation vis-à-vis the Chinese academic community, share best practices, learn from differing publishing models, and explore collaborations that have the potential to enhance the quality, reach, and diversity of our journals.

Looking ahead

It was a productive and friendly exchange that reflected our shared commitment to advancing scholarly communication and improving journal publishing practices. We value these visits, which allow us to create collaborations with stakeholders in the global academic community.

Our Basel office is a hub for hosting international delegations, partners, and collaborators. We look forward to creating more global connections that support our mission.

Impactful Research

Appointment of Dr. Tim Tait-Jamieson as Head of Publication Ethics

As part of our ongoing commitment to research integrity and publishing excellence, I am delighted to announce that we have appointed Dr. Tim Tait-Jamieson as Head of Publication Ethics.

In this role, Tim will lead the development of our ethics strategy and oversee the continued growth of the Publication Ethics Department, which is based across our offices in Basel, Manchester, Belgrade/Novi Sad, and Cluj. Guided by the principles of effective prevention and efficient resolution, the department plays an essential role in ensuring the highest standards of integrity throughout our editorial processes.

Department focus

Working closely with internal teams and external partners, the Publication Ethics Department focuses on refining our policies, aligning our operations with international best practices, and addressing complex cases with fairness and transparency. This work is critical in supporting our editors, reviewers, and authors, reinforcing MDPI’s contribution to the global dialogue on research integrity.

“Research integrity is something to which we all contribute through our daily work at MDPI”

About Tim

Tim joined MDPI in 2021 and has held several roles within the Publication Ethics Department, most recently serving as Research Integrity Lead. Based in our Basel office, he brings a strong academic background, with a Ph.D. in Geography from the University of Fribourg, Switzerland, and a proven track record of leadership in research integrity.

Research integrity is something to which we all contribute through our daily work at MDPI. I look forward to Tim’s leadership as we continue investing in the people, processes, and partnerships that uphold the trust and credibility of scholarly publishing.

Read more:

Inside MDPI

How and why MDPI offers Open Peer Review

At MDPI, we are committed to advancing openness and transparency in scholarly publishing. One area where we’ve taken a leadership role is peer review. Since 2014, MDPI has offered authors the option of open peer review, giving them the opportunity to publish reviewer comments alongside their papers. Each year, more authors are choosing this path, helping to build trust in the editorial process and provide valuable context for the research we publish.

Jack McKenna (Senior Content Specialist, MDPI) recently wrote an informative piece looking at the impact and importance of open peer review at MDPI. He highlights how this approach not only benefits readers but also gives well-deserved recognition to our reviewers, who generously dedicate their time and expertise to the academic community.

I encourage you to read this blogpost to see how MDPI is helping set standards for transparency in scholarly publishing.

Coming Together for Science

Recap of MDPI’s AIS 2025 Conference in Kuala Lumpur

Entering the month of August, we held The 2nd International Conference on AI Sensors and Transducers (AIS 2025) in Kuala Lumpur, Malaysia.

“AIS is quickly becoming a premier event in the field”

The second edition of AIS brought together 335 attendees from across Asia and beyond, including participants from China, Japan, Korea, and Southeast Asia. The event, chaired by Prof. Dr. Toshihiro Itoh (University of Tokyo), Prof. Dr. Sang-Woo Kim (Yonsei University), and Prof. Dr. Chengkuo Lee (National University of Singapore), continues to grow in reputation and has become an important platform for researchers and students to present their work, exchange ideas, and build international collaborations.

AIS is quickly becoming a premier event in the field, with participants highlighting its quality of service, its expanding academic network, and the value it delivers in the context of tightening research budgets in the region.

It was also excellent to see our new MDPI journal AI Sensors, which originated from a conference topic, host a successful launch party at the event.

Highlights from participant feedback:

  • Southeast University (China) sent a student delegation and considers AIS a regular fixture for Ph.D. students in need of international conference experience.
  • CAS Aerospace Information Research Institute sent a 10-member delegation and plans to further promote AIS internally.
  • Japanese researchers regard AIS as a must-attend event, placing it on a par with IEEE conferences and citing the benefits of networking and exchange.
  • Korean academics praised the organization and noted improved perceptions of MDPI among their institutions, viewing AIS as a strategic opportunity to deepen engagement in the region.

Award winners

We recognized the recipients of the Best Presentation, Best Scientist, Best Poster, and Best Student Paper awards, whose contributions set a standard for academic excellence. The full award announcement is available here.

Looking ahead

The 3rd International Conference on AI Sensors and Transducers will be held from 5 to10 August 2026 in Jeju, Korea. The General Chairs will be Prof. Inkyu Park (Korea Advanced Institute of Science and Technology), Prof. Zhou Li (Tsinghua University), Prof. Xinge Yu (City University of Hong Kong), and Prof. Chengkuo Lee (National University of Singapore). We look forward to bringing together innovators, researchers and experts who are shaping the future at the intersection of sensors, sensing technology, transducers and artificial intelligence.

Thank you

Our conference team managed this event with great agility and professionalism and are already planning improvements to make the conference even more accessible. Special thanks to the National University of Singapore for their support, and to our entire conference team and collaborators for their dedication.

AIS is gaining momentum, and we look forward to supporting its role as a bridge between MDPI and the global academic community.

“Our conference team managed this event with great agility and professionalism”

Closing Thoughts

Recognizing our outstanding reviewers

As we close this edition of the newsletter, I would like to spotlight MDPI’s 2024 Outstanding Reviewer Awards, which showcase a group of winners whose contributions often go unseen but are essential to the integrity of scholarly publishing: our reviewers.

In 2024, more than 215,000 reviewers dedicated their time and expertise to MDPI journals. From this community, we are proud to recognize 356 recipients of the Outstanding Reviewer Awards, who went above and beyond by providing timely, thorough and constructive feedback.

These awards are not only a token of our appreciation but also a reflection of the values we stand for: rigor, fairness and collaboration in advancing science.

To explore the full list of awardees across disciplines, from life sciences to the humanities, please visit the following pages:

About MDPI Awards

To recognize the academic community, MDPI journals regularly offer various awards to researchers in specific fields. Serving as a source of recognition and inspiration, these awards help increase the influence of scholars who have been credited with outstanding achievements and are making a significant contribution to the advancement of their respective fields.

To explore more opening Outstanding Reviewer Awards, please click here.

To all our reviewers: thank you for being the foundation of trust that makes open access publishing possible!

Stefan Tochev
Chief Executive Officer
MDPI AG

20 August 2025
Antibodies | Issue Cover Collection Published in 2023

1. “Characterization of Active MMP9 in Chronic Inflammatory Diseases Using a Novel Anti-MMP9 Antibody”
by Maile Velasquez, Chris O’Sullivan, Robert Brockett, Amanda Mikels-Vigdal, Igor Mikaelian, Victoria Smith and Andrew E. Greenstein
Antibodies 2023, 12(1), 9; https://doi.org/10.3390/antib12010009
Available online: https://www.mdpi.com/2073-4468/12/1/9

Cover Story: Matrix metalloproteinase 9 (MMP9), a protease implicated in multiple diseases, is secreted as an inactive zymogen and requires proteolytic removal of the pro-domain for activation. The relative levels and functionality of the pro- and active-MMP9 isoforms in tissues are not characterized. We generated a specific antibody that distinguishes an active form of MMP9, F107-MMP9, from the inactive pro-MMP9 isoform. Using multiple in vitro assays and specimen types, we show that F107-MMP9 expression is localized and disease-specific compared with its more abundant parental pro-form. It is detected around sites of active tissue remodeling, including fistulae of inflammatory bowel and dermal fissures in hidradenitis suppurativa, and is expressed by myeloid cells, including macrophages and neutrophils.

2. “CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases”
by Sara Gómez-Melero and Javier Caballero-Villarraso
Antibodies 2023, 12(2), 30; https://doi.org/10.3390/antib12020030
Available online: https://www.mdpi.com/2073-4468/12/2/30

Cover Story: The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor (GPCR) involved in a wide range of biological processes. When CCR6 binds to its sole ligand CCL20, a signaling network is produced. This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple sclerosis, HIV infection or rheumatoid arthritis. The CCR6/CCL20 axis plays a fundamental role in immune homeostasis and activation. Th17 cells express the CCR6 receptor and inflammatory cytokines, including IL-17, IL-21 and IL-22, which are involved in the spread of inflammatory response. The CCL20/CCR6 mechanism plays a crucial role in the recruitment of these pro-inflammatory cells to local tissues.

3. “Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy”
by Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen and Kar Muthumani
Antibodies 2023, 12(3), 46; https://doi.org/10.3390/antib12030046
Available online: https://www.mdpi.com/2073-4468/12/3/46

Cover Story: Harnessing the immune system to combat disease has revolutionized medical treatment. Monoclonal antibodies (mAbs), in particular, have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases, including allergies, autoimmune diseases, neurodegenerative disorders, cancer, and infectious diseases. These mAbs are developed from naturally occurring antibodies and target specific epitopes of single molecules, minimizing off-target effects. Antibodies can also be designed to target particular pathogens or modulate immune function by activating or suppressing certain pathways. Despite the benefit for patients, the production and administration of monoclonal antibody therapeutics are laborious, costly, and time-consuming.

4. “Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease”
by Weronika Grąźlewska and Lucyna Holec-Gąsior
Antibodies 2023, 12(4), 63; https://doi.org/10.3390/antib12040063
Available online: https://www.mdpi.com/2073-4468/12/4/63

Cover Story: Lyme disease is a tick-borne disease caused by spirochetes belonging to the Borrelia burgdorferi sensu lato complex. The disease is characterized by a varied course; therefore, the basis for diagnosis is laboratory methods. Currently, a two-tiered serological test is recommended, using an ELISA as a screening test and a Western blot as a confirmatory test. This approach was introduced due to the relatively high number of false-positive results obtained when using an ELISA alone. However, this approach has not entirely solved the problem of false-positive results caused by cross-reactive antibodies. Many highly immunogenic B. burgdorferi s.l. proteins are recognized nonspecifically by antibodies directed against other pathogens.

20 August 2025
Antibodies | Notable Review Papers Published in 2023–2024


Given that all articles published in Antibodies (ISSN: 2073-4468) are freely available in an open access format, we welcome you to read our notable review papers published in 2023 and 2024.

1. “CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases”
by Sara Gómez-Melero and Javier Caballero-Villarraso
Antibodies 2023, 12(2), 30; https://doi.org/10.3390/antib12020030
Available online: https://www.mdpi.com/2073-4468/12/2/30

2. “Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria”
by Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
Antibodies 2024, 13(1), 21; https://doi.org/10.3390/antib13010021
Available online: https://www.mdpi.com/2073-4468/13/1/21

3. “A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)”
by Kristin Widyasari and Jinnam Kim
Antibodies 2023, 12(1), 5; https://doi.org/10.3390/antib12010005
Available online: https://www.mdpi.com/2073-4468/12/1/5

4. “Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy”
by Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen and Kar Muthumani
Antibodies 2023, 12(3), 46; https://doi.org/10.3390/antib12030046
Available online: https://www.mdpi.com/2073-4468/12/3/46

5. “Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier”
by Toshihiko Tashima
Antibodies 2023, 12(3), 43; https://doi.org/10.3390/antib12030043
Available online: https://www.mdpi.com/2073-4468/12/3/43

6. “Non-Affinity Purification of Antibodies”
by Tsutomu Arakawa, Yui Tomioka, Masataka Nakagawa, Chiaki Sakuma, Yasunori Kurosawa, Daisuke Ejima, Kouhei Tsumoto and Teruo Akuta
Antibodies 2023, 12(1), 15; https://doi.org/10.3390/antib12010015
Available online: https://www.mdpi.com/2073-4468/12/1/15

7. “New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond”
by Marino Paroli, Chiara Gioia and Daniele Accapezzato
Antibodies 2023, 12(1), 25; https://doi.org/10.3390/antib12010025
Available online: https://www.mdpi.com/2073-4468/12/1/25

8. “IgA Nephropathy: Current Treatment and New Insights”
by Dimitra Petrou, Petros Kalogeropoulos, George Liapis and Sophia Lionaki
Antibodies 2023, 12(2), 40; https://doi.org/10.3390/antib12020040
Available online: https://www.mdpi.com/2073-4468/12/2/40

9. “Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature”
by Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier
Antibodies 2024, 13(1), 1; https://doi.org/10.3390/antib13010001
Available online: https://www.mdpi.com/2073-4468/13/1/1

10. “Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management”
by Panagiotis Gklinos and Ruth Dobson
Antibodies 2024, 13(2), 43; https://doi.org/10.3390/antib13020043
Available online: https://www.mdpi.com/2073-4468/13/2/43

31 July 2025
MDPI INSIGHTS: The CEO's Letter #25 - 8,000 Staff Worldwide, Korea Visit, 100,000 Preprints, Malaysia Roundtable, Canada Consortium Deal

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Talent Drives Our Progress

For the first time in MDPI’s history, we now have over 8,000 colleagues across the company. I would like to take a moment to celebrate this milestone and acknowledge the driving force behind our growth and success: our people.

As the world’s leading fully open access publisher, MDPI has grown thanks to the dedication, talent, and teamwork of colleagues across the company. Already halfway through 2025, we’ve welcomed nearly 2,000 new colleagues. 

“Our achievements are also about the people behind them”

We now manage over 475 journals, with 298 receiving an Impact Factor, and hundreds more indexed in major databases, including 343 in Scopus, and 92 by PubMed. As the reach and impact of our journals continues to grow, so does the need for dedicated and qualified teams to support that growth. Thus, attracting and retaining exceptional talent remains a cornerstone of our success.

Our achievements are not just about the results of journal expansion, however: they’re about the people behind them. From our hardworking editors to our meticulous English editing and production teams – from our journal relationship specialists, public relations, marketing and communications professionals to our conference teams and the project teams behind Preprints, Scilit, SciProfiles, JAMS and more. Our success reflects the work of thousands of people showing up each day, taking pride in their work, and committed to excellence and service.

What we’re doing to support talent:

  • Investing in onboarding and training to help new colleagues feel welcomed and empowered to thrive.
  • Creating clearer career paths across all functions, from editorial to communications and beyond.
  • Launching mentorship programs and internal knowledge-sharing sessions to promote growth and collaboration.
  • Evolving our recognition and rewards programs to better celebrate your contributions.
  • Expanding our training systems and platforms.

MDPI’s in-house training department offers over 215 training courses, covering topics from editorial development to cross-cultural collaboration. In 2024 alone, we had 44 full-time trainers and 196 part-time training assistants supporting the learning and development needs of colleagues worldwide. These efforts ensure our teams are equipped with the skills and confidence to grow professionally and contribute meaningfully.

Over two-thirds of our workforce is editorial, and of our more than 5,400 editors, 87% hold a Master’s degree and 6% a PhD. Their collective contributions are central to delivering a high-quality publishing experience and supporting global academic communication.

As we celebrate this milestone, we also aim to continue on a path of steady and sustainable growth, one that balances journal expansion with investment in people, outreach, processes, and innovation. Together, we are shaping the future of open access and academic publishing. Thank you for your hard work, your ideas, and your commitment to serving the global research community.

Let’s continue working together to create a culture where great talent grows and every colleague feels valued.

Impactful Research

Visiting South Korea: Building Connections and Supporting the MDPI Seoul Office

In July, I had the opportunity to visit our team in Seoul and engage directly with academic communities in South Korea. The visit focused on deepening MDPI’s relationships with local universities, institutions, and partners, and supporting the great work of our colleagues at the MDPI Seoul office.

Korea Association of Private University Libraries (KAPUL) Conference

A highlight of the visit was our participation in the Korea Association of Private University Libraries (KAPUL) Conference, where we presented to over 100 academic librarians. I delivered a keynote speech titled “The Evolving Publishing Landscape: Open Access and Beyond,” while my colleague Dr. Jisuk Kang (Public Affairs Specialist) shared insights in her presentation, “Inside MDPI: Editorial Practices & Research Integrity.”

Facts & Figures: South Korea

  • South Korea is MDPI’s sixth-largest publishing country by article volume (over 90,000 MDPI papers published to date).
  • In 2024, Korea ranked 16th globally by total publications, and 6th (among these top 20 countries) by citation impact.
  • 52% of Korean publications in 2024 were OA – and 73% of those were Gold OA.
  • MDPI published about 20% of all OA papers from Korea in 2024.
  • Over 2,000 active Editorial Board Members from South Korea contribute to MDPI journals, with 11 Section Editors-in-Chief.
  • We currently have 11 Institutional Open Access Program agreements and two society partnerships in Korea:
    • Korean Society of Pharmaceutical Sciences and Technology (with MDPI journal Pharmaceutics)
    • Korean Tribology Society (with MDPI journal Coatings)

MDPI Seoul Office and the First Korea Salon

Our Seoul office serves as a regional hub for marketing, communications, and community engagement. It continues to grow in size and influence, prioritizing supporting scholar visits, conference sponsorships, and outreach events such as the recent MDPI Korea Salon.

The inaugural Salon, themed “Exploring Research Trends in Medical Publishing, Ethics, and AI,” brought together over 20 scholars and Editorial Board members serving MDPI journals.

Thank you to our guest speakers including Professors Young-Joon Surh of Seoul National University, Kwang-Sig Lee of Korea University, and Jin-Won Noh of Yonsei University who presented on the landscape of medicine in South Korea and across the globe. The Salon also included presentations from MDPI colleagues on Open Access, ethics, and how the IOAP can support researchers in this field.

“Our Seoul office continues to grow in size and influence”

Looking Ahead

MDPI is already the leading OA publisher in South Korea, yet challenges and misconceptions around OA and APCs remain. Visits like this one, along with the ongoing efforts of our Seoul office, are important to building understanding, trust, and long-term relationships with the local academic community.

A big thank-you to our colleagues in Seoul for their warm hospitality, professionalism, and energy! Our new office is well situated, staffed, and ready to grow. This visit marked an important step forward in our continued mission to support global research communities and advance Open Science.

Inside MDPI

Preprints.org Reaches 100,000 Preprints: A Major Milestone for MDPI and Open Science

In case you missed it, Preprints.org recently surpassed 100,000 preprints posted. This is a major milestone for our platform and one worth celebrating.

Preprints are a key pillar of the Open Science movement, which promotes transparency, equity, and faster knowledge-sharing through initiatives such as Open Access, Open Data, Open Source, and Open Peer Review. The benefits of Open Science extend beyond researchers, as they support funders, educators, policymakers, and the public in advancing discovery and innovation.

What is behind the 100,000 preprints milestone?

Since its launch in 2016, Preprints.org has grown into one of the world’s leading preprint platforms, now ranked fifth globally by publication volume.

More than 350,000 researchers have contributed, helping shape this dynamic and collaborative space for sharing early-stage research across all disciplines.

Read the full announcement here:
https://www.mdpi.com/about/announcements/12202

“Preprints.org has grown into one of the world’s leading preprint platforms”

Some quick facts worth noting:

  • About 56% of the preprints on Preprints.org are later published in peer-reviewed journals.
  • The platform is now indexed in Web of Science (Preprint Citation Index), Europe PMC, and Crossref, helping improve visibility and trust in the preprints shared.
  • Recent upgrades – including a revamped website, new features such as search subscriptions, curated reading lists, and community feedback tools (PREreview) – show our commitment to developing Preprints.org in line with researchers’ needs.

This growth and progress would not be possible without the dedication of the Preprints.org team, our Advisory Board members, screeners, and colleagues across MDPI who support the platform’s development. This milestone is a reminder of our shared mission: to accelerate scientific communication and build a more open, transparent, and inclusive research ecosystem.

I’m excited to see what’s ahead as we approach Preprints.org’s 10-year anniversary in 2026!

Coming Together for Science

Malaysia Media Roundtable: Educating on Open Access and MDPI’s Presence in Southeast Asia

At the end of June, I had the opportunity to participate in a strategic media roundtable in Kuala Lumpur, focused on raising awareness about the importance of Open Access (OA) and on MDPI’s growing presence in Southeast Asia.

We welcomed five Malaysian media outlets for an engaging private session that included presentations and open discussion.

I gave an overview of the benefits of Open Access, MDPI’s global developments, and our collaborations in Malaysia.

My colleague Yu Nwe Soe (Public Relations Specialist), presented on our editorial process, helping to clarify how MDPI supports authors and maintains research quality.

We were also joined by two local Editorial Board Members (EBMs) who offered first-hand insights into their experiences working with MDPI and how OA has shaped their publishing choices.

The discussion covered a range of questions from the press, from OA publishing models to editorial standards, and highlighted MDPI’s unique contribution to accelerating scientific communication in the region.

As the leading fully OA publisher, we see it as our responsibility to continue educating research communities and the broader public on the impact of OA, especially in emerging and high-growth academic markets.

Spotlight on Malaysia

Malaysia continues to rise as a regional research hub, with five universities ranked in the global top 200 and 11 subjects in the global top 50. In 2024, Malaysia ranked 2nd in Southeast Asia in total publication output, 10th in Asia, and 25th globally.

MDPI’s presence in Malaysia:

  • Over 21,000 research articles published to date from Malaysian institutions
  • More than 1,100 articles published in 2024 alone
  • In the period 2020–2024, 54% of Malaysia’s total publications were OA
  • 36 EBMs from Malaysia, across 27 MDPI journals
  • Around 100 conferences sponsored in Malaysia in the past five years
  • MDPI is hosting the 2nd International Conference on AI Sensors and Transducers in Kuala Lumpur (29 July- 3 August 2025)

Media Coverage & Editorial Voices

Following the roundtable, we saw positive coverage across several local outlets, with articles highlighting MDPI’s role in empowering Malaysian researchers. Notable pieces included:

Our local EBMs also shared their perspectives:

Prof. Denny Ng Kok Sum (Sunway University, EBM of MDPI journal Processes) and Prof. Lee (EBM of MDPI journal Bacteria) share their experiences with MDPI and the role Open Access plays in their publication decisions.

“We see it as our responsibility to continue educating research communities on the impact of OA”

“I didn’t want my work stuck behind a paywall.”
— Prof. Denny Ng Kok Sum, Sunway University, Processes Editorial Board Member

“Open Access opens doors for collaboration and visibility, especially in fast-developing regions like ours.”
— Prof. Lee, Bacteria Editorial Board Member

This roundtable marked another step in building trust, understanding, and collaboration in Southeast Asia. A big thank-you to the MDPI Malaysia team and all those who contributed to the event’s success.

Closing Thoughts

MDPI Signs First North American Agreement with Canadian Consortium

We are proud to announce a major milestone for MDPI Canada and an important step forward for OA in North America.

In July, our Toronto office finalized MDPI’s first North American consortium agreement with the Federal Science Libraries Network (FSLN). This is a significant achievement that strengthens our expansion in Canada and reinforces our global commitment to supporting Open Science.

This two-year agreement gives Canadian federal agencies access to MDPI’s IOAP, including discounted article processing charges for affiliated researchers across our portfolio of over 475 OA journals. It lowers barriers for Canadian scientists to share their work more openly and reach a global audience.


Ryan Siu, Institutional Partnerships Manager at MDPI.

“The Open Science landscape in Canada is rapidly evolving, with the Tri-Agency Open Access Policy set for renewal by the end of 2025. This reflects ongoing efforts to foster greater scientific transparency and accessibility at a national policy level,” says Ryan Siu, Institutional Partnerships Manager at MDPI.

“Our new agreement with FSLN represents our shared commitment to further these efforts and foster wider readership. By aligning with these initiatives, we make progress towards research that’s both inclusive and impactful, benefiting local and global communities alike.”

Participating FSLN institutions include:

  • Agriculture and Agri-Food Canada
  • Environment and Climate Change Canada
  • Health Canada
  • National Research Council Canada
  • Natural Resources Canada

By partnering with some of Canada’s largest science-based agencies, we reaffirm our goal of advancing OA across continents. We look forward to developing our support for Canadian researchers and continuing to drive progress in Open Science across North America and beyond.

Stefan Tochev
Chief Executive Officer
MDPI AG

29 July 2025
Meet Us at the 5th International Symposium on Frontiers in Molecular Science, 26–29 August 2025, Kyoto, Japan


The 5th International Symposium on Frontiers in Molecular Science (ISFMS2025), organized by the International Journal of Molecular Sciences (ISSN: 1422-0067) and MDPI, will be held from 26 to 29 August 2025 in Kyoto, Japan.

This conference will present outstanding research results that elucidate the molecular mechanisms of biological functions and regulation and will also facilitate drug design based on molecular biology, biophysical characterization, in vivo environmental homeostasis, organ interactions based on sensory systems, the physiome, and AI-assisted analysis of protein structures and functions. It aims to bring together scientists, researchers, and engineers from across the world who are working in academia, national labs, and industry to discuss the latest advances in molecular science.

Topics that will be covered include, but are not limited to, the following:

  • Protein structure and function;
  • Multidomain proteins;
  • Drug design and drug resistance;
  • Enzymes;
  • Molecular biology of galectins;
  • Glycobiophysics;
  • NMR spectroscopy;
  • Specific sensory systems;
  • Brain and systemic function.

The following MDPI journals will be represented at this conference:

  • International Journal of Molecular Sciences;
  • Current Issues in Molecular Biology;
  • Cells;
  • Bioengineering;
  • Biophysica;
  • BioTech;
  • Cancers;
  • International Journal of Translational Medicine;
  • Kinases and Phosphatases;
  • Microorganisms;
  • Molecules;
  • Synbio;
  • Antibiotics;
  • Antioxidants;
  • Applied Biosciences;
  • BioMed;
  • Biomedicines;
  • BioMedInformatics;
  • Membranes;
  • Antibodies.

If you are planning to attend this conference, please feel free to reach out online and start a conversation with us. Our delegates look forward to meeting you in person at our booth and answering any questions you may have. For more information about this event, please click on the following link:  https://sciforum.net/event/ISFMS2025.

29 July 2025
Antibodies | Exclusive Interview with Prof. Dr. Traian Sulea—Session 1 Chair of the 1st International Online Conference by Antibodies


With a strong background in bio, organic, and physical chemistry, I am an established computational chemist with over 25 years of experience and broad expertise in molecular modeling applied to (bio)pharmaceutical research; ranging from cheminformatics-based small-molecule lead discovery and optimization to structural bioinformatics-based computational biology, and from molecular simulations of protein-ligand complexes to engineering of therapeutic proteins and antibody humanization.

Name: Prof. Dr. Traian Sulea
Affiliation: National Research Council Canada, Montreal, Canada
Research interests: health, biotechnology, biotherapeutics, chemistry, information technology, modelling software

The following is a short interview with Prof. Dr. Traian Sulea:

  1. Could you please briefly introduce yourself?

I am the Principal Research Officer and Team Leader of Molecular Modeling at the National Research Council Canada, which I joined as a post-doctoral fellow in 1995. I have also been an Adjunct Professor at the Institute of Parasitology of McGill University since 2012, where I teach structural bioinformatics and therapeutic antibody design. My expertise in applying computational approaches to the discovery and optimization of bioactive small-molecules and biologics includes the development of computational methods for biomolecular applications with a focus on continuum solvation and binding affinity predictions, structure-based engineering of protein fusions, selective targeting of solid tumor microenvironment, and antibody optimization via humanization, affinity maturation, selective conjugation, and developability assessment. I have authored over 150 publications, including 110 peer-reviewed articles, 38 international patents, and 5 book chapters.

  1. What do you think of the development status and trends of open access publishing?

Huge strides have been made in making scientific research widely accessible to everyone. More and more scientific studies and associated data are freely available, and I believe this trend will continue. Peer-reviewing is also an important process of scientific publishing, and much debate has been shared lately on the quality of this process, which can certainly benefit from fine-tuning and improvement, perhaps also via adding a component involving a wider community-based evaluation of submitted papers.

  1. What is your impression of the Antibodies journal?

Antibodies is a journal addressing a niche area of research that lacks sufficient publishing venues. With a relatively well-reputed history and track record, it definitely has huge potential to become one of the leading journals in this field of antibody research, where both fundamental and applied science can find their homes.

  1. What do you think will be the research hotspots in the field of antibodies in the next few years, and can you describe them to us?

I think that even higher-throughput methods for screening even larger antibody libraries will always be in vogue in the field of antibody discovery, characterization, and optimization towards drug candidates with unparalleled medical benefits. As a molecular modeler and computational structural biologist, I am in awe of the latest advances in antibody structure prediction methods, and so I am certain computational methods based on artificial intelligence and deep learning from large datasets will be the next hotspot of this field for the next while.

  1. Can you give any advice on academic research for young scholars in related fields?

Emerging young scientists should get involved in the field of therapeutic antibody engineering and pay particular attention to the fast-paced developments in artificial intelligence, which are on the verge of reshaping the discovery and optimization of antibody drugs in the near future.

  1. Could you kindly share with us your thoughts and outlook on this E-conference?

I believe this is a timely conference in the field of therapeutic antibody discovery and development. I hope the research presented throughout the conference will be positioned at the forefront of the field and, therefore, able to spur much interest and further advances. It also has the potential to boost the visibility of the Antibodies journal to the relevant audience. The organizing committee has assembled an excellent team of high-profile scientists serving in various roles, like conference and session chairs, as well as selection committee members, and has been able to invite renowned scientists to deliver keynote lectures and oral presentations. It is my belief that this first edition will serve as a stepping stone towards defining this conference as a must-attend event in the future.

  1. Could you please provide a brief introduction to the session you are chairing, titled “Computational Antibody Engineering”?

In silico design and optimization of antibodies for therapeutic applications has gained significant traction in the past decade. It builds on the solid foundation established for classical methods in protein structure-based modeling, combined with the recent breakthrough of artificial intelligence in protein structure prediction. Recognition of these achievements in 2024 by the Nobel Prize in Chemistry demonstrated the value carried by these computational protein engineering methods, with far-reaching potential practical applications in therapeutic antibody discovery and development. This timely session thus welcomes contributions describing the latest refinements of established classical physics-based computational methods as well as the recent developments of rapidly evolving artificial intelligence-based approaches. Presentations will cover computational predictions of antibody–antigen binding affinity, specificity, docking and epitope mapping, predictions of antibody biophysical properties such as stability, aggregation, and immunogenicity, design and triage of antibody libraries for hit enrichment and downstream manufacturability, molecular engineering of novel antibody modalities, and entirely in silico antibody discovery efforts.

4 July 2025
MDPI’s Newly Launched Journals in June 2025

Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.

We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

Journal Founding Editor-in-Chief Journal Topics (Selected)
Prof. Dr. Chang-Pu Sun,
China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China
Editorial | View inaugural issue
quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods
View journal scope | Submit an article
Prof. Dr. Hualiang Lin,
Sun Yat-sen University, China;
Prof. Dr. Jose L. Domingo,
Universitat Rovira i Virgili, Spain
Editorial | View inaugural issue
green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health |
View journal scope | Submit an article
Prof. Dr. Francesco Veglio,
University of L’Aquila, Italy
Editorial | View inaugural issue
ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies
View journal scope | Submit an article
Prof. Dr. Junxing Zheng,
Huazhong University of Science and Technology, China
Editorial | View inaugural issue
computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management
View journal scope | Submit an article
Prof. Dr. Assunta Di Vaio,
University of Naples Parthenope, Italy
Editorial | View inaugural issue
sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure
View journal scope | Submit an article
Prof. Dr. Changjun Liu,
Sichuan University, China
Editorial | View inaugural issue
bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication
View journal scope | Submit an article
We wish to thank everyone who has supported the development of open access publishing. If you are interested in launching a new open access journal with us, you are welcome to send an application here.

2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI’s 2024 Impact Factor Highlights

For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.

While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.

“These results reflect the trust that the scholarly community places in MDPI”

MDPI’s 2024 Impact Factor Highlights

  • 298 MDPI journals received a Journal Impact Factor.
  • 60 journals earned their first-ever Impact Factor
    • To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
    • Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
  • 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
    • What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
  • 116 of our previously ranked journals increased their Impact Factor.
  • 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.

These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.

Open Access with Impact

As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.

Further Reading

If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.

You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.

Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.

Impactful Research

MDPI Journals See Continued Growth in 2024 CiteScore Results

Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.

2024 Highlights:

  • 322 MDPI journals received a CiteScore (up from 274 last year).
  • 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
  • 237 journals (85%) saw an increase in their CiteScore compared to last year.
  • 48 journals received a CiteScore for the first time.
  • 39 journals are now placed in the top 10% of their subject areas.

“This growth highlights our commitment to supporting open, trusted science”

What is CiteScore and how is it measured?

CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.

Why is this important?

These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.

Inside MDPI

Highlights from the MDPI USA Summit in Boston (5–6 June)

With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.

Why do we organize MDPI Summits?

These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:

  1. Share MDPI’s values, achievements, editorial practices, and local market collaborations.
  2. Collect feedback on MDPI operations and journal practices.
  3. Empower Chief Editors to confidently represent MDPI beyond the Summit.

While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.

About the Boston Summit

Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.

Agenda Highlights:

Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:

  • MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
  • AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
  • MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
  • Panel Discussion – Stefan, Feichi, Giulia, Claudia
  • Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
  • Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)

MDPI & the USA: Facts and Figures

  • With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
  • In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
  • As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
  • As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
  • Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
  • MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.

A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.

Coming Together for Science

Highlights from the MDPI France Summit in Paris (12–13 June)

We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.

Why a France Summit?

We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.

“Our authors and editors very much enjoy working with us”

Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:

This is not accurate.

A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.

The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.

Summit Overview

Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.

Summit Feedback

The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:

  • “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
  • “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
  • “Very well organized! A great opportunity to see all French MDPI partners and editors.”

Program Highlights:

Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:

  • MDPI Overview and France Collaboration – Stefan Tochev (CEO)
  • MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
  • Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
  • AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
  • Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
  • Closing Remarks – Stefan Tochev
  • Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan

MDPI & France: Facts and Figures

  • With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
  • As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
  • As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
  • Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
  • In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.

Special thanks to our colleagues from Romanian offices for organizing this successful event.

Closing Thoughts

Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award

As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.

I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.

A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.

About the Tu Youyou Award
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honour the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award recognizing exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.

For further information about the award and the winners, please visit the Tu Youyou Award website.

Stefan Tochev
Chief Executive Officer
MDPI AG

Back to TopTop